Article written by Bruce Sylvester A new meta-analysis of clinical trial data suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2), used to treat heart failure, also reduce the risk… read more.
Article written by Bruce Sylvester Researchers from a large European study, which included the UK, report that while patients are often able to reduce risks of cardiovascular events… read more.
Article written by Bruce Sylvester Among patients with a history of heart problems, prediabetes increases risks of heart disease and death, researchers reported on July 15, 2020 in… read more.
AstraZeneca announced high-level results from Farxiga’s (dapagliflozin) Phase III DAPA-CKD trial showed a statistically significant and clinically meaningful effect on its primary endpoint of a composite of worsening… read more.
Article written by Bruce Sylvester Glycated hemoglobin A1c (HbA1c) greater than 7% correlates with an increased risk of cardiovascular events in elderly patients..
Genentech, a member of the Roche Group announced detailed results from the Phase III Archway study evaluating its investigational Port Delivery System with ranibizumab (PDS) for the treatment… read more.
The Phase III study FIDELIO-DKD evaluating the efficacy and safety of BAY 94 8862 (finerenone), from Bayer, versus placebo when added to standard of care for chronic kidney… read more.
Gilead Sciences, Inc. announced data demonstrating the safety and efficacy of the once-daily, single tablet regimen Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in… read more.
Mundipharma announces that the European Commission (EC) has approved the extension of the indication of Invokana (canagliflozin) to include important renal outcome data from the landmark Canagliflozin and… read more.
Boehringer Ingelheim have announced the results of a sub-group analysis from the CAROLINA cardiovascular outcome trial focusing on Asian adults with type 2 diabetes mellitus and elevated cardiovascular… read more.
Article written by Bruce Sylvester In a study published on June 2, 2020 in Diabetologia, researchers reported that ertugliflozin preserves renal function in type 2 diabetics with baseline… read more.
Glenmark Pharmaceuticals announced the launch of antiviral drug FabiFlu (favipiravir) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
